ABSTRACT
Objective Discovery of fetal cell-free DNA fragments in maternal blood revolutionized prenatal diagnostics. Although non-invasive prenatal testing (NIPT) is already a matured screening test with high specificity and sensitivity, the accurate estimation of the proportion of fetal fragments, called fetal fraction, is crucial to avoid false-negative results.
Methods We collected 6999 samples from women undergoing NIPT testing with a single male fetus to demonstrate the influence of fetal fraction by the maternal and fetal characteristics.
Results We show several fetal fraction discrepancies that contradict the generally presented conventional view. At first, the fetal fraction is not consistently rising with the maturity of the fetus due to a drop in 15 weeks of maturation. Secondly, the male samples have a lower fetal fraction than female fetuses, arguably due to the smaller gonosomal chromosomes. Finally, we discuss not only the possible reasons why this inconsistency exists but we also outline why these differences have not yet been identified and published.
Conclusion We demonstrate two non-intuitive trends to better comprehend the fetal fraction development and more precise selection of patients with sufficient fetal fraction for accurate testing.
What is already known about this topic?
Non-invasive prenatal testing has become a well-known mature screening test, and the fetal fraction is studied in detail by research teams worldwide.
What does this study add?
Here we demonstrate two non-intuitive trends to better comprehend fetal fraction development that can further increase the sensitivity of routine testing by proper selection of blood sampling according to gestational age and fetus gender.
Competing Interest Statement
J.G., R.H., J.B., M.K., F.D., J.R., and T.S. are the employees of Geneton Ltd., which participated in the development of the commercial NIPT test in Slovakia. M.S. is an employee of Trisomytest Ltd. and Medirex Group Academy, which provides NIPT tests in Slovakia. All remaining authors have declared no conflicts of interest.
Funding Statement
This article was created with the support of the OP Integrated Infrastructure for the project: Long term strategic research and development focused on the occurrence of Lynch syndrome in the Slovak population and possibilities of prevention of tumors associated with this syndrome, ITMS: 313011V578, co-financed by the European Regional Development Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethical Committee of the Bratislava Self-Governing Region gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of interest statement: J.G., R.H., J.B., M.K., F.D., J.R., and T.S. are the employees of Geneton Ltd., which participated in the development of the commercial NIPT test in Slovakia. M.S. is an employee of Trisomytest Ltd. and Medirex Group Academy, which provides NIPT tests in Slovakia. All remaining authors have declared no conflicts of interest.
Funding statement: This article was created with the support of the OP Integrated Infrastructure for the project: Long term strategic research and development focused on the occurrence of Lynch syndrome in the Slovak population and possibilities of prevention of tumors associated with this syndrome, ITMS: 313011V578, co-financed by the European Regional Development Fund.
Data availability statement: Data are available on request from the corresponding author.
Data Availability
All data produced in the present study are available upon reasonable request to the authors.